title: A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination.
abstract: Certain pathogens recruit host complement inhibitors such as factor H (fH) to evade the immune system. Microbial complement inhibitor-binding molecules can be promising vaccine targets by eliciting Abs that neutralize this microbial defense mechanism. One such Ag, meningococcal factor H-binding protein (fHbp), was used in clinical trials before the protein was discovered to bind fH. The potential effect of fH binding on vaccine immunogenicity had not been assessed in experimental animals because fHbp binds human fH specifically. In this study, we developed a human fH transgenic mouse model. Transgenic mice immunized with fHbp vaccine had 4- to 8-fold lower serum bactericidal Ab responses than those of control mice whose native fH did not bind the vaccine. In contrast, Ab responses were unimpaired in transgenic mice immunized with a control meningococcal group C polysaccharide-protein conjugate vaccine. In transgenic mice, immunization with an fH nonbinding mutant of fHbp elicited Abs with higher bactericidal activity than that of fHbp vaccination itself. Abs elicited by the mutant fHbp more effectively blocked fH binding to wild-type fHbp than Abs elicited by fHbp that bound fH. Thus, a mutant fHbp vaccine that does not bind fH but that retains immunogenicity is predicted to be superior in humans to an fHbp vaccine that binds human fH. In the case of mutant fHbp vaccination, the resultant Ab responses may be directed more at epitopes in or near the fH binding site, which result in greater complement-mediated serum bactericidal activity; these epitopes may be obscured when human fH is bound to the wild-type fHbp vaccine.
authors.affiliation: Center for Immunobiology and Vaccine Development, Children's Hospital Oakland Research Institute, Oakland, CA 94609, USA.
authors.forename: Peter T
authors.initials: PT
authors.lastname: Beernink
authors.forename: Jutamas
authors.initials: J
authors.lastname: Shaughnessy
authors.forename: Emily M
authors.initials: EM
authors.lastname: Braga
authors.forename: Qin
authors.initials: Q
authors.lastname: Liu
authors.forename: Peter A
authors.initials: PA
authors.lastname: Rice
authors.forename: Sanjay
authors.initials: S
authors.lastname: Ram
authors.forename: Dan M
authors.initials: DM
authors.lastname: Granoff
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism; D000328:Adult; D019943:Amino Acid Substitution / Q000235:genetics* / Q000276:immunology; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis* / Q000097:blood; D000942:Antigens, Bacterial / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D001426:Bacterial Proteins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D001667:Binding, Competitive / Q000276:immunology; D001770:Blood Bactericidal Activity / Q000276:immunology; D017242:Complement Factor H / Q000378:metabolism; D005260:Female; D006801:Humans; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008822:Mice, Transgenic; D009345:Neisseria meningitidis / Q000235:genetics / Q000276:immunology; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; C493495:CFH protein, human; D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate; C484699:factor H-binding protein, Neisseria meningitidis; D017242:Complement Factor H